You just read:

Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

News provided by

Viking Therapeutics, Inc.

Jun 05, 2018, 07:01 ET